Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease
- PMID: 29892066
- PMCID: PMC6039259
- DOI: 10.1038/s41591-018-0051-5
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease
Abstract
Activation of microglia by classical inflammatory mediators can convert astrocytes into a neurotoxic A1 phenotype in a variety of neurological diseases1,2. Development of agents that could inhibit the formation of A1 reactive astrocytes could be used to treat these diseases for which there are no disease-modifying therapies. Glucagon-like peptide-1 receptor (GLP1R) agonists have been indicated as potential neuroprotective agents for neurologic disorders such as Alzheimer's disease and Parkinson's disease3-13. The mechanisms by which GLP1R agonists are neuroprotective are not known. Here we show that a potent, brain-penetrant long-acting GLP1R agonist, NLY01, protects against the loss of dopaminergic neurons and behavioral deficits in the α-synuclein preformed fibril (α-syn PFF) mouse model of sporadic Parkinson's disease14,15. NLY01 also prolongs the life and reduces the behavioral deficits and neuropathological abnormalities in the human A53T α-synuclein (hA53T) transgenic mouse model of α-synucleinopathy-induced neurodegeneration16. We found that NLY01 is a potent GLP1R agonist with favorable properties that is neuroprotective through the direct prevention of microglial-mediated conversion of astrocytes to an A1 neurotoxic phenotype. In light of its favorable properties, NLY01 should be evaluated in the treatment of Parkinson's disease and related neurologic disorders characterized by microglial activation.
Conflict of interest statement
Z.M., V.L.D., S.L., T.M.D., H.S.K are co-founders of Neuraly Inc. and hold ownership equity in the company. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. V.V.R. is the CSO of Neuraly Inc.
Figures




Comment in
-
Fire prevention in the Parkinson's disease brain.Nat Med. 2018 Jul;24(7):900-902. doi: 10.1038/s41591-018-0109-4. Nat Med. 2018. PMID: 29988138 No abstract available.
-
Glial GLP1R: A novel neuroprotector?Mov Disord. 2018 Dec;33(12):1877. doi: 10.1002/mds.27547. Epub 2018 Nov 14. Mov Disord. 2018. PMID: 30427545 No abstract available.
References
-
- Liddelow SA, Barres BA. Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity. 2017;46:957–967. - PubMed
-
- Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discov Today. 2016;21:802–818. - PubMed
-
- Chen S, et al. Glucagon-like peptide-1 protects hippocampal neurons against advanced glycation end product-induced tau hyperphosphorylation. Neuroscience. 2014;256:137–146. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Molecular Biology Databases